Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Stroke

  Free Subscription


Articles published in Lancet Neurol

Retrieve available abstracts of 129 articles:
HTML format



Single Articles


    June 2025
  1. SPOSATO LA, Ayan D, Ahmed M, Fridman S, et al
    Extended CT angiography versus standard CT angiography for the detection of cardioaortic thrombus in patients with ischaemic stroke and transient ischaemic attack (DAYLIGHT): a prospective, randomised, open-label, blinded end-point trial.
    Lancet Neurol. 2025;24:489-499.
    PubMed     Abstract available


  2. MANLEY GT, Dams-O'Connor K, Alosco ML, Awwad HO, et al
    A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative.
    Lancet Neurol. 2025;24:512-523.
    PubMed     Abstract available



  3. Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial.
    Lancet Neurol. 2025;24:500-511.
    PubMed     Abstract available


  4. MARSAN E, Gutman D, Hohman TJ, Phatak M, et al
    The Path-NeuroDegeneration consortium.
    Lancet Neurol. 2025;24:482.
    PubMed    


  5. NOGUEIRA RG, Bhatt N, Haussen DC, Moehlenbruch MA, et al
    Endovascular treatment of distal arterial occlusions: a more distant reality than ever?
    Lancet Neurol. 2025;24:478-480.
    PubMed    


  6. GARCIA-ESPERON C, Parsons MW
    Shedding DAYLIGHT on atrial thrombus in hyperacute stroke.
    Lancet Neurol. 2025;24:472-473.
    PubMed    


    May 2025
  7. DONNERS SJA, van Velzen TJ, Cheng SF, Gregson J, et al
    Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial.
    Lancet Neurol. 2025;24:389-399.
    PubMed     Abstract available


  8. HO JK, Hankey GJ
    Carotid revascularisation for carotid stenosis.
    Lancet Neurol. 2025;24:372-373.
    PubMed    


    April 2025
  9. CAVALCANTE F, Treurniet K, Kaesmacher J, Kappelhof M, et al
    Intravenous thrombolysis before endovascular treatment versus endovascular treatment alone for patients with large vessel occlusion and carotid tandem lesions: individual participant data meta-analysis of six randomised trials.
    Lancet Neurol. 2025;24:305-315.
    PubMed     Abstract available


  10. SALMAN RA, Thrippleton MJ
    Pharmacological therapy for cerebral cavernous malformations.
    Lancet Neurol. 2025;24:276-277.
    PubMed    


    March 2025
  11. SCHLAUG G, Cassarly C, Feld JA, Wolf SL, et al
    Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trial.
    Lancet Neurol. 2025 Mar 26:S1474-4422(25)00044.
    PubMed     Abstract available


  12. MIZIELINSKA S, Hautbergue GM, Gendron TF, van Blitterswijk M, et al
    Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics.
    Lancet Neurol. 2025;24:261-274.
    PubMed     Abstract available


  13. VAN DE MUNCKHOF A, van Kammen MS, Tatlisumak T, Krzywicka K, et al
    Direct oral anticoagulants versus vitamin K antagonists for cerebral venous thrombosis (DOAC-CVT): an international, prospective, observational cohort study.
    Lancet Neurol. 2025;24:199-207.
    PubMed     Abstract available


    February 2025
  14. PRICE C
    Neuroprotection in acute ischaemic stroke: reasons for optimism?
    Lancet Neurol. 2025 Feb 4:S1474-4422(25)00007.
    PubMed    


  15. TYMIANSKI M, Hill MD, Goyal M, Christenson J, et al
    Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: a post-hoc meta-analysis of individual patient data from three randomised trials.
    Lancet Neurol. 2025 Feb 4:S1474-4422(24)00515.
    PubMed     Abstract available


  16. SHOAMANESH A, Field TS, Coutts SB, Sharma M, et al
    Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.
    Lancet Neurol. 2025;24:140-151.
    PubMed     Abstract available


  17. LIU R, Zhao J, Rudd AG
    From stroke awareness to stroke action awareness.
    Lancet Neurol. 2025;24:96.
    PubMed    


  18. SPOSATO LA, Wachter R
    Anticoagulation for patients with device-detected atrial fibrillation and a history of stroke.
    Lancet Neurol. 2025;24:92-94.
    PubMed    


  19. MOENS TG, Da Cruz S, Neumann M, Shelkovnikova TA, et al
    Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications.
    Lancet Neurol. 2025;24:166-178.
    PubMed     Abstract available


  20. COLEMAN KKL, Berry S, Cummings J, Hsiung GR, et al
    Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.
    Lancet Neurol. 2025;24:128-139.
    PubMed     Abstract available


  21. HABIB AA, Zhao C, Aban I, Franca MC Jr, et al
    Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Lancet Neurol. 2025;24:117-127.
    PubMed     Abstract available


  22. ANTOZZI C, Vu T, Ramchandren S, Nowak RJ, et al
    Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
    Lancet Neurol. 2025;24:105-116.
    PubMed     Abstract available


    January 2025
  23. YANG P, Zhang Y, Liu J
    Ischaemic stroke in 2024: progress on multiple fronts.
    Lancet Neurol. 2025;24:7-8.
    PubMed    


    December 2024
  24. GETTINGS JV, Mohammad Alizadeh Chafjiri F, Patel AA, Shorvon S, et al
    Diagnosis and management of status epilepticus: improving the status quo.
    Lancet Neurol. 2024 Dec 2:S1474-4422(24)00430.
    PubMed     Abstract available


  25. SHETH KN, Albers GW, Saver JL, Campbell BCV, et al
    Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.
    Lancet Neurol. 2024;23:1205-1213.
    PubMed     Abstract available


  26. LIU Q, Mo S, Wu J, Tong X, et al
    Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, randomised trial.
    Lancet Neurol. 2024;23:1195-1204.
    PubMed     Abstract available


    November 2024
  27. TURC G, Nguyen TN
    Reconsidering prourokinase for acute ischaemic stroke.
    Lancet Neurol. 2024 Nov 28:S1474-4422(24)00474.
    PubMed    


  28. LI S, Gu HQ, Feng B, Li H, et al
    Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.
    Lancet Neurol. 2024 Nov 28:S1474-4422(24)00436.
    PubMed     Abstract available


  29. KRUYT ND, Nederkoorn PJ, Sandset EC, Lyden P, et al
    A cautionary view on blood pressure lowering in patients with acute ischaemic stroke receiving reperfusion therapy.
    Lancet Neurol. 2024 Nov 25:S1474-4422(24)00438.
    PubMed    


  30. MUIR KW, Ford GA, Ford I, Wardlaw JM, et al
    Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.
    Lancet Neurol. 2024;23:1087-1096.
    PubMed     Abstract available


  31. BRALEY TJ, Ehde DM, Alschuler KN, Little R, et al
    Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial.
    Lancet Neurol. 2024;23:1108-1118.
    PubMed     Abstract available


  32. PALAIODIMOU L, Tsivgoulis G
    A new standard for thrombolysis in acute ischaemic stroke.
    Lancet Neurol. 2024;23:1064-1065.
    PubMed    


    October 2024
  33. LIM SY, Tan AH, Ahmad-Annuar A, Okubadejo NU, et al
    Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic.
    Lancet Neurol. 2024 Oct 21:S1474-4422(24)00378.
    PubMed     Abstract available


  34. VOLOVICI V, Cenzato M, Meling TR
    The European expertise network for open microvascular surgery.
    Lancet Neurol. 2024 Oct 11:S1474-4422(24)00409.
    PubMed    



  35. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Neurol. 2024;23:973-1003.
    PubMed     Abstract available


  36. WU S, Liu M
    Global burden of stroke: dynamic estimates to inform action.
    Lancet Neurol. 2024;23:952-953.
    PubMed    


  37. AMEZCUA L, Rotstein D, Shirani A, Ciccarelli O, et al
    Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia.
    Lancet Neurol. 2024;23:1050-1062.
    PubMed     Abstract available


  38. CORREALE J, Solomon AJ, Cohen JA, Banwell BL, et al
    Differential diagnosis of suspected multiple sclerosis: global health considerations.
    Lancet Neurol. 2024;23:1035-1049.
    PubMed     Abstract available


    September 2024
  39. CANEVELLI M, Jackson-Tarlton C, Rockwood K
    Frailty for neurologists: perspectives on how frailty influences care planning.
    Lancet Neurol. 2024 Sep 11:S1474-4422(24)00291.
    PubMed     Abstract available


  40. OSPEL JM, Ganesh A, Goyal M
    Pragmatic outcomes for stroke research.
    Lancet Neurol. 2024;23:860-862.
    PubMed    


  41. YOGENDRAKUMAR V, Lin L, Medcalf RL, Parsons MW, et al
    Improving thrombolysis efficiency for acute ischaemic stroke.
    Lancet Neurol. 2024;23:853-855.
    PubMed    


    August 2024
  42. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
    Dietary intervention for post-stroke dysphagia - Authors' reply.
    Lancet Neurol. 2024;23:764-765.
    PubMed    


  43. SHIMIZU A, Yamaguchi K, Kunieda K, Ohno T, et al
    Dietary intervention for post-stroke dysphagia.
    Lancet Neurol. 2024;23:763-764.
    PubMed    


  44. THE LANCET NEUROLOGY
    A real chance to reduce death and disability from stroke.
    Lancet Neurol. 2024;23:749.
    PubMed    


    July 2024
  45. MORIMOTO T, Sakakibara F
    Endovascular thrombectomy for large ischaemic stroke: outcomes beyond 90 days.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00290.
    PubMed    


  46. THOMALLA G, Fiehler J, Subtil F, Bonekamp S, et al
    Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00278.
    PubMed     Abstract available


  47. SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al
    gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236.
    PubMed     Abstract available


  48. BOURCIER R, Marnat G, Dargazanli C, Zhu F, et al
    Safety and efficacy of stent retrievers plus contact aspiration in patients with acute ischaemic anterior circulation stroke and positive susceptibility vessel sign in France (VECTOR): a randomised, single-blind trial.
    Lancet Neurol. 2024;23:700-711.
    PubMed     Abstract available


  49. ABDALKADER M, Nguyen TN
    Susceptibility vessel sign and endovascular stroke therapy.
    Lancet Neurol. 2024;23:653-654.
    PubMed    


    June 2024
  50. GAO F, Tong X, Jia B, Wei M, et al
    Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
    Lancet Neurol. 2024 Jun 21:S1474-4422(24)00186.
    PubMed     Abstract available


  51. CAMPBELL BCV
    Durable benefit of thrombectomy 6-24 h after stroke onset.
    Lancet Neurol. 2024 Jun 20:S1474-4422(24)00261.
    PubMed    


  52. HUIJBERTS I, Pinckaers FME, Olthuis SGH, van Kuijk SMJ, et al
    Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial in the Netherlands.
    Lancet Neurol. 2024 Jun 20:S1474-4422(24)00228.
    PubMed     Abstract available


  53. PARSONS MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, et al
    Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
    Lancet Neurol. 2024 Jun 13:S1474-4422(24)00206.
    PubMed     Abstract available


  54. TOYODA K
    Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?
    Lancet Neurol. 2024 Jun 13:S1474-4422(24)00258.
    PubMed    


  55. ALI M, van Etten ES, Akoudad S, Schaafsma JD, et al
    Haemorrhagic stroke and brain vascular malformations in women: risk factors and clinical features.
    Lancet Neurol. 2024;23:625-635.
    PubMed     Abstract available


  56. THE LANCET NEUROLOGY
    Forging ahead in haemorrhagic stroke research.
    Lancet Neurol. 2024;23:545.
    PubMed    


  57. SISODIYA SM, Gulcebi MI, Fortunato F, Mills JD, et al
    Climate change and disorders of the nervous system.
    Lancet Neurol. 2024;23:636-648.
    PubMed     Abstract available


    May 2024
  58. OLAVARRIA VV
    Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke.
    Lancet Neurol. 2024 May 15:S1474-4422(24)00208.
    PubMed    


  59. ZONNEVELD TP, Vermeer SE, van Zwet EW, Groot AED, et al
    Safety and efficacy of active blood-pressure reduction to the recommended thresholds for intravenous thrombolysis in patients with acute ischaemic stroke in the Netherlands (TRUTH): a prospective, observational, cluster-based, parallel-group study.
    Lancet Neurol. 2024 May 15:S1474-4422(24)00177.
    PubMed     Abstract available


  60. SARFO FS, Gebreyohanns M, Akinyemi R, Ebenezer AA, et al
    The African Stroke Organization Conference 2023.
    Lancet Neurol. 2024;23:459-460.
    PubMed    


  61. CORTESE I, Norato G, Harrington PR, Usher T, et al
    Biomarkers for progressive multifocal leukoencephalopathy: emerging data for use of JC virus DNA copy number in clinical trials.
    Lancet Neurol. 2024;23:534-544.
    PubMed     Abstract available


  62. PELLINEN J, Foster EC, Wilmshurst JM, Zuberi SM, et al
    Improving epilepsy diagnosis across the lifespan: approaches and innovations.
    Lancet Neurol. 2024;23:511-521.
    PubMed     Abstract available


    April 2024
  63. YASSI N, Zhao H, Churilov L, Wu TY, et al
    Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial.
    Lancet Neurol. 2024 Apr 19:S1474-4422(24)00128.
    PubMed     Abstract available



  64. Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial.
    Lancet Neurol. 2024 Apr 17:S1474-4422(24)00096.
    PubMed     Abstract available


  65. GUSTAVSSON EK, Follett J, Trinh J, Barodia SK, et al
    RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
    Lancet Neurol. 2024 Apr 10:S1474-4422(24)00121.
    PubMed     Abstract available


  66. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
    Dysphagia after stroke: research advances in treatment interventions.
    Lancet Neurol. 2024;23:418-428.
    PubMed     Abstract available


  67. SEIFFGE DJ, Cancelloni V, Raber L, Paciaroni M, et al
    Secondary stroke prevention in people with atrial fibrillation: treatments and trials.
    Lancet Neurol. 2024;23:404-417.
    PubMed     Abstract available


  68. SPOSATO LA, Andrade JG, Field TS
    Detection of atrial fibrillation in patients after stroke - Authors' reply.
    Lancet Neurol. 2024;23:336-337.
    PubMed    


  69. SIONTIS KC, Noseworthy PA, Friedman PA
    Detection of atrial fibrillation in patients after stroke.
    Lancet Neurol. 2024;23:335-336.
    PubMed    


  70. KANDEL A, Arjyal A, Karmacharya B, Gajurel B, et al
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:334.
    PubMed    


  71. FEIGIN VL, Yaria J, Owolabi M
    Pragmatic solutions for the global burden of stroke - Authors' reply.
    Lancet Neurol. 2024;23:334-335.
    PubMed    


  72. SCHLOGL M, Quinn TJ
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:333-334.
    PubMed    



  73. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Neurol. 2024;23:344-381.
    PubMed     Abstract available


    February 2024
  74. MAZIGHI M, Kohrmann M, Lemmens R, Lyrer PA, et al
    Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
    Lancet Neurol. 2024;23:157-167.
    PubMed     Abstract available


  75. GANESH A
    Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke.
    Lancet Neurol. 2024;23:125-127.
    PubMed    


  76. SIMUNI T, Chahine LM, Poston K, Brumm M, et al
    A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research.
    Lancet Neurol. 2024;23:178-190.
    PubMed     Abstract available


  77. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available


    January 2024
  78. SHARMA M, Molina CA, Toyoda K, Bereczki D, et al
    Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Lancet Neurol. 2024;23:46-59.
    PubMed     Abstract available


  79. KHATRI P
    Anticoagulants to prevent recurrent non-cardioembolic stroke.
    Lancet Neurol. 2024;23:3-5.
    PubMed    


  80. ANDERSON CS
    Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage.
    Lancet Neurol. 2024;23:12-13.
    PubMed    


    December 2023
  81. BRIGO F
    The (hi)story of stroke.
    Lancet Neurol. 2023;22:1110.
    PubMed    


  82. UCHIYAMA S
    Anticoagulation in people with atrial fibrillation after intracranial haemorrhage.
    Lancet Neurol. 2023;22:1091-1092.
    PubMed    


  83. ABBOTT A, Schott L, Gao L, Budincevic H, et al
    Carotid artery overtreatment in the USA.
    Lancet Neurol. 2023;22:1102-1103.
    PubMed    


    November 2023
  84. KOPCZAK A, Stringer MS, van den Brink H, Kerkhofs D, et al
    Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial.
    Lancet Neurol. 2023;22:991-1004.
    PubMed     Abstract available


  85. RUBIANO AM, Lee K
    Traumatic brain injury research: homogenising heterogeneity.
    Lancet Neurol. 2023;22:973-975.
    PubMed    


  86. ADAMS D, Sekijima Y, Conceicao I, Waddington-Cruz M, et al
    Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
    Lancet Neurol. 2023;22:1061-1074.
    PubMed     Abstract available


    October 2023
  87. MIRELMAN A, Rochester L, Simuni T, Hausdoff JM, et al
    Digital mobility measures to predict Parkinson's disease.
    Lancet Neurol. 2023 Oct 18:S1474-4422(23)00376.
    PubMed    


  88. SPOSATO LA, Field TS, Schnabel RB, Wachter R, et al
    Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00326.
    PubMed     Abstract available


  89. AL-SHAHI SALMAN R, Stephen J, Tierney JF, Lewis SC, et al
    Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00315.
    PubMed     Abstract available


  90. KAMEL H
    Reassessing the implications of atrial fibrillation detected after stroke.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00406.
    PubMed    


  91. BRUSCA SB, Albert MA
    Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00386.
    PubMed    


  92. WATKINS DA
    Policy priorities for preventing stroke-related mortality and disability worldwide.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00387.
    PubMed    


  93. FEIGIN VL, Owolabi MO
    Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission.
    Lancet Neurol. 2023 Oct 6:S1474-4422(23)00277.
    PubMed    


  94. MARCUCCI M, Chan MTV, Smith EE, Absalom AR, et al
    Prevention of perioperative stroke in patients undergoing non-cardiac surgery.
    Lancet Neurol. 2023;22:946-958.
    PubMed     Abstract available


  95. IZZY S, Grashow R, Radmanesh F, Chen P, et al
    Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention.
    Lancet Neurol. 2023;22:959-970.
    PubMed     Abstract available


    September 2023
  96. HUGGER SS, Do TP, Ashina H, Goicochea MT, et al
    Migraine in older adults.
    Lancet Neurol. 2023 Sep 13:S1474-4422(23)00206.
    PubMed     Abstract available


  97. LABEIT B, Michou E, Hamdy S, Trapl-Grundschober M, et al
    The assessment of dysphagia after stroke: state of the art and future directions.
    Lancet Neurol. 2023;22:858-870.
    PubMed     Abstract available


  98. FENG W
    Diagnosis of post-stroke dysphagia: towards better treatment.
    Lancet Neurol. 2023;22:778-779.
    PubMed    


  99. OSPEL JM, Goyal M
    Prehospital triage in acute stroke: which questions to ask?
    Lancet Neurol. 2023;22:771-772.
    PubMed    


  100. D'GAMA AM, Mulhern S, Sheidley BR, Boodhoo F, et al
    Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study.
    Lancet Neurol. 2023;22:812-825.
    PubMed     Abstract available


  101. GUTERUD M, Fagerheim Bugge H, Roislien J, Kramer-Johansen J, et al
    Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial.
    Lancet Neurol. 2023;22:800-811.
    PubMed     Abstract available


    August 2023
  102. ODDO M, Taccone FS, Petrosino M, Badenes R, et al
    The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study.
    Lancet Neurol. 2023 Aug 28:S1474-4422(23)00271.
    PubMed     Abstract available


  103. RIZIG M, Bandres-Ciga S, Makarious MB, Ojo OO, et al
    Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
    Lancet Neurol. 2023 Aug 23:S1474-4422(23)00283.
    PubMed     Abstract available


  104. SOLOMON AJ, Arrambide G, Brownlee WJ, Flanagan EP, et al
    Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
    Lancet Neurol. 2023;22:750-768.
    PubMed     Abstract available


  105. MEADOR KJ, Cohen MJ, Loring DW, Matthews AG, et al
    Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.
    Lancet Neurol. 2023;22:712-722.
    PubMed     Abstract available


  106. MAYNARD G, Kannan R, Liu J, Wang W, et al
    Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
    Lancet Neurol. 2023;22:672-684.
    PubMed     Abstract available


  107. GILADI N, Alcalay RN, Cutter G, Gasser T, et al
    Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2023;22:661-671.
    PubMed     Abstract available


    July 2023
  108. ENGLISH C, Ramage E
    Secondary stroke prevention: more questions than answers.
    Lancet Neurol. 2023 Jul 25:S1474-4422(23)00278.
    PubMed    


  109. SCHWARZBACH CJ, Eichner FA, Rucker V, Hofmann AL, et al
    The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00216.
    PubMed     Abstract available


  110. DESBOROUGH MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al
    Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Lancet Neurol. 2023;22:557-567.
    PubMed     Abstract available


  111. FRISONI GB, van der Flier W
    STRIVEing to describe small vessel disease.
    Lancet Neurol. 2023;22:548-549.
    PubMed    


  112. GRANIT V, Benatar M, Kurtoglu M, Miljkovic MD, et al
    Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
    Lancet Neurol. 2023;22:578-590.
    PubMed     Abstract available


  113. CORBOY JR, Fox RJ, Kister I, Cutter GR, et al
    Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
    Lancet Neurol. 2023;22:568-577.
    PubMed     Abstract available


  114. MEISEL A
    Are CAR T cells the answer to myasthenia gravis therapy?
    Lancet Neurol. 2023;22:545-546.
    PubMed    


    June 2023
  115. VAN DER MERWE J
    Stroke care quality-why recognition matters.
    Lancet Neurol. 2023;22:471.
    PubMed    


  116. HAYWARD KS, Bernhardt J
    Aspiring to restore arm and hand function after stroke.
    Lancet Neurol. 2023;22:464-465.
    PubMed    


    May 2023
  117. DUERING M, Biessels GJ, Brodtmann A, Chen C, et al
    Neuroimaging standards for research into small vessel disease-advances since 2013.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00131.
    PubMed     Abstract available


  118. KOEMANS EA, Chhatwal JP, van Veluw SJ, van Etten ES, et al
    Progression of cerebral amyloid angiopathy: a pathophysiological framework.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00114.
    PubMed     Abstract available


  119. HOWARD JF JR, Bresch S, Genge A, Hewamadduma C, et al
    Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Neurol. 2023;22:395-406.
    PubMed     Abstract available


  120. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Lancet Neurol. 2023;22:383-394.
    PubMed     Abstract available


  121. KASKI D, Koohi N, Haider S, Chandratheva A, et al
    The hyperacute vestibular syndrome: ear or brain?
    Lancet Neurol. 2023;22:377-378.
    PubMed    


    April 2023
  122. WU S, Anderson CS
    Antiplatelets for secondary stroke prevention in China.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00130.
    PubMed    


  123. PAN Y, Meng X, Yuan B, Johnston SC, et al
    Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00113.
    PubMed     Abstract available


  124. LAVALLEE PC, Charles H, Albers GW, Caplan LR, et al
    Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study.
    Lancet Neurol. 2023;22:320-329.
    PubMed     Abstract available


  125. SAMUELS N, van de Graaf RA, Mulder MJHL, Brown S, et al
    Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.
    Lancet Neurol. 2023;22:312-319.
    PubMed     Abstract available


  126. BERNHARDT J, Corbett D, Dukelow S, Savitz S, et al
    The International Stroke Recovery and Rehabilitation Alliance.
    Lancet Neurol. 2023;22:295-296.
    PubMed    


  127. MAZIGHI M
    The quest for optimal blood pressure management after stroke.
    Lancet Neurol. 2023;22:285-286.
    PubMed    


  128. FEIGIN VL, Brainin M, Martins SCO
    The polypill from a public-health perspective.
    Lancet Neurol. 2023;22:294-295.
    PubMed    


    March 2023
  129. TSIVGOULIS G, Katsanos AH, Sandset EC, Turc G, et al
    Thrombolysis for acute ischaemic stroke: current status and future perspectives.
    Lancet Neurol. 2023 Mar 9:S1474-4422(22)00519.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stroke is free of charge.